Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses1
暂无分享,去创建一个
A. Sette | R. Chesnut | D. Bundle | J. Alexander | M. del Guercio | J. Fikes | S. Defrees | A. Maewal | J. Paulson | Lei Qiao
[1] A. Lindberg,et al. Glycoprotein conjugate vaccines. , 1999, Vaccine.
[2] S. Hoffman,et al. Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. , 1999, Vaccine.
[3] R. Meloen,et al. Epitope polarity and adjuvants influence the fine specificity of the humoral response against Semliki Forest virus specific peptide vaccines. , 1998, Vaccine.
[4] F. Marincola,et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] Alessandro Sette,et al. The optimization of helper T lymphocyte (HTL) function in vaccine development , 1998, Immunologic research.
[6] S. Hoffman,et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. , 1997, Vaccine.
[7] C. Partidos,et al. Protection against morbillivirus-induced encephalitis by immunization with a rationally designed synthetic peptide vaccine containing B- and T-cell epitopes from the fusion protein of measles virus , 1995, Journal of virology.
[8] J. Mekalanos,et al. Acetylation (O-factor 5) affects the structural and immunological properties of Salmonella typhimurium lipopolysaccharide O antigen , 1995, Infection and immunity.
[9] C. Kensil,et al. Structural and immunological characterization of the vaccine adjuvant QS-21. , 1995, Pharmaceutical biotechnology.
[10] A. Vitiello,et al. Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. , 1995, Pharmaceutical biotechnology.
[11] A. Fattom,et al. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. , 1995, Vaccine.
[12] M. Powell,et al. Vaccine Design , 1995, Pharmaceutical Biotechnology.
[13] C Oseroff,et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.
[14] A. Ragauskas,et al. Molecular recognition of a Salmonella trisaccharide epitope by monoclonal antibody Se155-4. , 1994, Biochemistry.
[15] S. Gangloff,et al. Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes , 1994, Infection and Immunity.
[16] T. Barington,et al. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine , 1994, Infection and immunity.
[17] R. Hunter,et al. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines. , 1993, Journal of immunology.
[18] H. Snippe,et al. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus , 1993, Journal of virology.
[19] S. Hoffman,et al. Monoclonal antibodies of three different immunoglobulin G isotypes produced by immunization with a synthetic peptide or native protein protect mice against challenge with Plasmodium yoelii sporozoites , 1993, Infection and immunity.
[20] A. Lanzavecchia. Identifying strategies for immune intervention. , 1993, Science.
[21] I. Pastan,et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A , 1993, Infection and immunity.
[22] D. Morrison,et al. Bacterial Endotoxic Lipopolysaccharides , 1992 .
[23] H. Caldwell,et al. Immunogenicity of a chimeric peptide corresponding to T helper and B cell epitopes of the Chlamydia trachomatis major outer membrane protein , 1992, The Journal of experimental medicine.
[24] J. Poolman,et al. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines , 1991, Infection and immunity.
[25] J. H. van de Wijgert,et al. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution , 1991, Infection and immunity.
[26] J. Poolman,et al. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice. , 1991, Journal of immunology.
[27] R. Arnon. Synthetic peptides as the basis for vaccine design. , 1991, Molecular immunology.
[28] J. Berzofsky. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. , 1991, Biotechnology therapeutics.
[29] D. Kasper,et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. , 1990, The Journal of clinical investigation.
[30] Milich Dr. Synthetic peptides: prospects for vaccine development. , 1990 .
[31] R. Schneerson,et al. Polysaccharide-protein conjugates: a new generation of vaccines. , 1990, The Journal of infectious diseases.
[32] D. Milich. Synthetic peptides: prospects for vaccine development. , 1990, Seminars in immunology.
[33] M. Mitchell,et al. Synthetic immunogens constructed from T-cell and B-cell stimulating peptides (T:B chimeras): preferential stimulation of unique T- and B-cell specificities is influenced by immunogen configuration. , 1990, Cellular immunology.
[34] Antonio Lanzavecchia,et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.
[35] R. Woods,et al. Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenzae type B (Hib) conjugate vaccine. , 1989, Advances in experimental medicine and biology.
[36] A. Vink,et al. Virally induced modulation of murine IgG antibody subclasses , 1988, The Journal of experimental medicine.
[37] R. Lerner,et al. Immune response to uncoupled peptides of foot-and-mouth disease virus. , 1987, Immunology.
[38] B. Plikaytis,et al. Pneumococcal vaccine efficacy in selected populations in the United States. , 1986, Annals of internal medicine.
[39] C. Leclerc,et al. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. , 1985, Journal of immunology.
[40] M. Meldal,et al. Immunochemistry of SalmonellaO-antigens: Studies of Salmonella BO antigen epitopes by enzyme-linked immunosorbent inhibition assays , 1985 .
[41] S. Michalek,et al. Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. , 1984, Journal of Immunology.
[42] B. M. Pinto,et al. Preparation of glycoconjugates for use as artificial antigens: a simplified procedure. , 1983, Carbohydrate research.
[43] S. Feig,et al. Pneumococcal vaccination of recipients of bone marrow transplants. , 1983, Archives of internal medicine.
[44] R. Lerner,et al. Synthetic peptide immunogens as vaccines. , 1983, Annual review of microbiology.
[45] D. Briles,et al. Mouse IgG3 antibodies are highly protective against infection with Streptococcus pneumoniae , 1981, Nature.
[46] C. Lugowski,et al. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. , 1981, Journal of immunology.
[47] M. H. da Silva,et al. Trypanosoma cruzi: role of different antibody classes in protection against infection in the mouse. , 1981, Experimental parasitology.
[48] A. Lindberg,et al. Artificial Salmonella Vaccines: Salmonella typhimurium O-Antigen-Specific Oligosaccharide-Protein Conjugates Elicit Protective Antibodies in Rabbits and Mice , 1981, Infection and immunity.
[49] A. Sutton,et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates , 1980, The Journal of experimental medicine.
[50] B. Greenwood,et al. IMPAIRMENT OF THE IMMUNE RESPONSE TO VACCINATION AFTER ACUTE MALARIA , 1978, The Lancet.
[51] I. Weissman,et al. Lymphoid tissue architecture. III. Germinal centers, T cells, and thymus-dependent vs thymus-independent antigens. , 1976, Advances in experimental medicine and biology.
[52] I. Weissman,et al. Lymphoid tissue architecture. II. Ontogeny of peripheral T and B cells in mice: evidence against Peyer's patches as the site of generation of B cells. , 1974, Journal of immunology.
[53] H. Spiegelberg,et al. Biological activities of immunoglobulins of different classes and subclasses. , 1974, Advances in immunology.
[54] H. Nikaido,et al. CHAPTER 4 – Isolation and Chemical and Immunological Characterization of Bacterial Lipopolysaccharides , 1971 .
[55] J. Humphrey,et al. STUDIES ON GLOBULIN AND ANTIBODY PRODUCTION IN MICE THYMECTOMIZED AT BIRTH. , 1964, Immunology.